IP Library › Granted Patent US 11,285,207

Granted Patent B2

US 11,285,207 · App. 15/944,394 · Granted Mar 29, 2022

Bispecific antibodies specifically binding to PD1 and LAG3

Inventors: Laura Codarri Deak (Schlieren, CH); Jens Fischer (Penzburg, DE); Sabine Imhof-Jung (Penzberg, DE); Christian Klein (Schlieren, CH); Stefan Seeber (Penzberg, DE); Patrick Alexander Aaron Weber (Schlieren, CH)

Assignee: Hoffmann-La Roche Inc.

A61K39/3955 A61K35/17 A61K39/001102 A61P31/12 A61P35/00 C07K16/2803 C07K16/2809 C07K16/2818 C07K16/3007 A61K45/06 A61K2039/505 A61K2039/507 A61K2300/00 C07K2317/24 C07K2317/31 C07K2317/33 C07K2317/41 C07K2317/52 C07K2317/522 C07K2317/526 C07K2317/55 C07K2317/64 C07K2317/66 C07K2317/71 C07K2317/74 C07K2317/75 C07K2317/76 C07K2317/77 C07K2317/92 C07K2317/94 C07K2319/00 C07K2319/30 C07K2319/74 C07K2319/75

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 11,285,207
App. No.: 15/944,394
Granted: Mar 29, 2022
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The invention relates to bispecific antibodies comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3. The invention further relates to methods of producing these molecules and to methods of using the same.

Claims (116)

1. A bispecific antibody comprising a first antigen binding domain that specifically binds to programmed cell death protein 1 (PD1) and a second antigen binding domain that specifically binds to Lymphocyte activation gene-3 (LAG3), wherein

said first antigen binding domain specifically binding to PD1 comprises

a VH domain comprising

(i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:1,

(ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:2, and

(iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:3; and

a VL domain comprising

(i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4;

(ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5, and

(iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:6 and

the second antigen binding domain that specifically binds to LAG3 comprises

(a) a VH domain comprising

(i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:14,

(ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:15, and

(iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:16; and

a VL domain comprising

(i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:17,

(ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:18, and

(iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:19; or

(b) a VH domain comprising

(i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:22,

(ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:23, and

(iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:24; and

a VL domain comprising

(i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:25,

(ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:26, and

(iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:27, or

(i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:30,

(ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:31, and

(iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:32, and

a VL domain comprising

(i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:33,

(ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:34, and

(iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:35, or

(d) a VH domain comprising

(i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:38,

(ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:39, and

(iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:40, and

a VL domain comprising

(i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:41,

(ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:42, and

(iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:43, or

(e) a VH domain comprising

(i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:46,

(ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:47, and

(iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:48, and

a VL domain comprising

(i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:49,

(ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:50, and

(iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:51.

2. The bispecific antibody of claim 1 , wherein the bispecific antibody comprises a Fc domain that is an IgG and wherein the Fc domain comprises one or more amino acid substitution that reduces binding to an Fc receptor.

3. The bispecific antibody according to claim 1 , wherein the first antigen-binding domain specifically binding to PD1 comprises

(a) a VH domain comprising the amino acid sequence of SEQ ID NO: 7 and a VL domain comprising the amino acid sequence of SEQ ID NO: 8, or

(b) a VH domain comprising the amino acid sequence of SEQ ID NO: 9 and a VL domain comprising the amino acid sequence of SEQ ID NO: 10, or

(c) a VH domain comprising the amino acid sequence of SEQ ID NO: 9 and a VL domain comprising the amino acid sequence of SEQ ID NO: 11, or

(d) a VH domain comprising the amino acid sequence of SEQ ID NO: 9 and a VL domain comprising the amino acid sequence of SEQ ID NO: 12, or

(e) a VH domain comprising the amino acid sequence of SEQ ID NO: 9 and a VL domain comprising the amino acid sequence of SEQ ID NO: 13.

4. The bispecific antibody according to claim 1 , wherein the first antigen-binding domain specifically binding to PD1 comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 9 and a VL domain comprising the amino acid sequence of SEQ ID NO: 10.

5. The bispecific antibody according to claim 3 , wherein the second antigen-binding domain specifically binding to LAG3 comprises

(a) a VH domain comprising the amino acid sequence of SEQ ID NO: 20 and a VL domain comprising the amino acid sequence of SEQ ID NO: 21, or

(b) a VH domain comprising the amino acid sequence of SEQ ID NO: 28 and a VL domain comprising the amino acid sequence of SEQ ID NO: 29, or

(c) a VH domain comprising the amino acid sequence of SEQ ID NO: 36 and a VL domain comprising the amino acid sequence of SEQ ID NO: 37, or

(d) a VH domain comprising the amino acid sequence of SEQ ID NO: 44 and a VL domain comprising the amino acid sequence of SEQ ID NO: 45, or

(e) a VH domain comprising the amino acid sequence of SEQ ID NO: 52 and a VL domain comprising the amino acid sequence of SEQ ID NO: 53.

6. The bispecific antibody according to claim 1 , wherein

the first antigen binding domain specifically binding to PD1 comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 9 and a VL domain comprising the amino acid sequence of SEQ ID NO: 10,

and the second antigen binding domain specifically binding to LAG3 comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 20 and a VL domain comprising the amino acid sequence of SEQ ID NO: 21 or a VH domain comprising the amino acid sequence of SEQ ID NO: 52 and a VL domain comprising the amino acid sequence of SEQ ID NO: 53.

7. The bispecific antibody according to claim 1 , wherein

8. The bispecific antibody of claim 1 , wherein the bispecific antibody comprises an Fc domain of human IgG1 subclass with the amino acid mutations L234A, L235A and P329G (numbering according to Kabat EU index).

9. The bispecific antibody of claim 1 , wherein the bispecific antibody comprises an Fc domain comprising a modification promoting the association of the first and second subunit of the Fc domain.

10. The bispecific antibody of claim 9 , wherein the first subunit of the Fc domain comprises the amino acid substitutions S354C and T366W (numbering according to Kabat EU index) and the second subunit of the Fc domain comprises the amino acid substitutions Y349C, T366S and Y407V (numbering according to Kabat EU index).

11. The bispecific antibody of claim 1 , wherein the bispecific antibody comprises an Fc domain, a first Fab fragment comprising the antigen binding domain that specifically binds to PD1 and a second Fab fragment comprising the antigen binding domain that specifically binds to LAG3.

12. The bispecific antibody of claim 11 , wherein in one of the Fab fragments the variable domains VL and VH are replaced by each other so that the VH domain is part of the light chain and the VL domain is part of the heavy chain.

13. The bispecific antibody of claim 11 , wherein in the first Fab fragment comprising the antigen binding domain that specifically binds to PD1 the variable domains VL and VH are replaced by each other.

14. The bispecific antibody of claim 11 , wherein the first Fab fragment comprising the antigen binding domain that specifically binds to PD1 or the second Fab fragment comprising the antigen binding domain that specifically binds to LAG3 comprises a Fab fragment wherein in the constant domain CL the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat EU Index), and in the constant domain CH1 the amino acids at positions 147 and 213 are substituted independently by glutamic acid (E) or aspartic acid (D) (numbering according to Kabat EU index).

15. The bispecific antibody of claim 11 , wherein in the second Fab fragment comprising the antigen binding domain that specifically binds to LAG3 the constant domain CL the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat EU Index), and in the constant domain CH1 the amino acids at positions 147 and 213 are substituted independently by glutamic acid (E) or aspartic acid (D) (numbering according to Kabat EU index).

16. The bispecific antibody of claim 1 , comprising

(a) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 96, a first light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 98,

a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 97, and a second light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO:99, or

(b) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 96, a first light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 98,

a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 100, and a second light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO:101, or

(c) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 102, a first light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 104,

a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 103, and a second light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO:105, or

(d) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 106, a first light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 107,

17. The bispecific antibody of claim 1 , comprising a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 96, a first light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 98, a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 100, and a second light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO:101.

18. The bispecific antibody of claim 11 , wherein the bispecific antibody comprises a second Fab fragment comprising the antigen binding domain that specifically binds to LAG3 which is fused to the C-terminus of the Fc domain.

19. The bispecific antibody of claim 18 , comprising a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 96, a first light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 98, a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 144, and a second light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO:101.

20. The bispecific antibody of claim 11 , wherein the bispecific antibody comprises a third Fab fragment comprising an antigen binding domain that specifically binds to LAG3.

21. The bispecific antibody of claim 11 , wherein the Fab fragment comprising the antigen binding domain that specifically binds to PD1 is fused via a peptide linker to the C-terminus of one of the heavy chains.

22. The bispecific antibody of claim 21 , comprising

(a) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 118, a first light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 115,

a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 119, and two second light chains comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO:101, or

(b) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 120, a first light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 115,

a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 121, and two second light chains comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO:99, or

(c) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 122, a first light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 115,

a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 103, and two second light chains comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO:105.

23. The bispecific antibody of claim 11 , wherein one of the Fab fragments comprising the antigen binding domain that specifically binds to LAG3 is fused via a peptide linker to the C-terminus of one of the heavy chains.

24. The bispecific antibody of claim 23 , comprising (a) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 96, a first light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 98, a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 145, and two second light chains comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO:101.

25. The bispecific antibody of claim 20 , wherein the bispecific antibody comprises a fourth Fab fragment comprising an antigen binding domain that specifically binds to PD1.

26. The bispecific antibody of claim 25 , wherein the two Fab fragments comprising each an antigen binding domain that specifically binds to PD1 are identical.

27. The bispecific antibody of claim 25 , wherein the two Fab fragments comprising each an antigen binding domain that specifically binds to PD1 are each fused via a peptide linker to the C-terminus to one of the heavy chains, respectively.

28. The bispecific antibody of claim 27 , comprising

(a) two heavy chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 114, two first light chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 115, and two second light chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 101, or

(b) two heavy chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 116, two first light chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 115, and two second light chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO:99, or

(c) two heavy chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 117, two first light chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 115, and two second light chains comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO:105.

29. The bispecific antibody of claim 1 , wherein the bispecific antibody comprises an Fc domain, two Fab fragments comprising each an antigen binding domain that specifically binds to LAG3 and a single chain Fab (scFab) comprising the antigen binding domain that specifically binds to PD1.

30. The bispecific antibody of claim 29 , wherein the scFab comprising an antigen binding domain that specifically binds to PD1 is fused via a peptide linker to the C-terminus to one of the heavy chains.

31. The bispecific antibody of claim 30 , comprising

(a) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 123, a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 119, and two light chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 101, or

(b) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 124, a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 121, and two light chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO:99, or

(c) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 125, a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 103, and a second light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO:105.

32. The bispecific antibody of claim 1 , comprising a first heavy chain comprising an amino acid sequence of SEQ ID NO: 96, a first light chain comprising an amino acid sequence of SEQ ID NO: 98, a second heavy chain comprising an amino acid sequence of SEQ ID NO: 100, and a second light chain comprising an amino acid sequence of SEQ ID NO:101.

Assignments (5)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2018

From: FISCHER, JENS; IMHOF-JUNG, SABINE; SEEBER, STEFAN

To: ROCHE DIAGNOSTICS GMBH

Reel/Frame 047765/0101 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2018

From: CODARRI DEAK, LAURA; KLEIN, CHRISTIAN; WEBER, PATRICK ALEXANDER AARON

To: ROCHE GLYCART AG

Reel/Frame 047765/0213 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2018

From: ROCHE DIAGNOSTICS GMBH

To: F. HOFFMANN-LA ROCHE AG